guest ::
| Home > Articles > Published articles > Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy |
| Home > Articles > Published articles > Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy |
(Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
| Date: | 2024 |
| Abstract: | New therapies to treat or prevent viral infections are essential, as recently observed during the COVID-19 pandemic. Here, we propose a therapeutic strategy based on monoclonal antibodies that block the specific interaction between the host receptor Siglec-1/CD169 and gangliosides embedded in the viral envelope. Antibodies are an excellent option for treating infectious diseases based on their high specificity, strong targeting affinity, and relatively low toxicity. Through a process of humanization, we optimized monoclonal antibodies to eliminate sequence liabilities and performed biophysical characterization. We demonstrated that they maintain their ability to block viral entry into myeloid cells. These molecular improvements during the discovery stage are key if we are to maximize efforts to develop new therapeutic strategies. Humanized monoclonal antibodies targeting CD169 provide new opportunities in the treatment of infections caused by ganglioside-containing enveloped viruses, which pose a constant threat to human health. In contrast with current neutralizing antibodies that bind antigens on the infectious particle, our antibodies can prevent several types of enveloped viruses interacting with host cells because they target the host CD169 protein, thus becoming a potential pan-antiviral therapy. |
| Grants: | Agencia Estatal de Investigación PID2020-117145RB-I00 European Commission 101046118 Agencia Estatal de Investigación PID2022-139271OB-I00 Agencia Estatal de Investigación PID2019-109870RB-I00 Agencia Estatal de Investigación CB21/13/00063 European Commission 101057100 European Commission 101095606 Fundació la Marató de TV3 202130 Fundació la Marató de TV3 201330 Fundació la Marató de TV3 201331 Fundació la Marató de TV3 201332 |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Antibody therapy ; Antivirals ; Humanization ; Methods ; Monoclonal antibody |
| Published in: | Biomedicine & pharmacotherapy, Vol. 175 (june 2024) , p. 116726, ISSN 1950-6007 |
